Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study.

The Lancet. Oncology·2026
Same author

Common γ-chain cytokines induce an epigenomically plastic precursor-like KIT<sup>+</sup> ILC2 state linked to immune disease susceptibility.

The Journal of allergy and clinical immunology·2026
Same author

Repeatability of AI-quantified incidental findings on lung cancer screening CT scans in the NELSON trial.

European radiology·2026
Same author

CT-based body composition and its change through time in relation to outcomes in participants screened for lung cancer.

EBioMedicine·2026
Same author

Identification of Shared Regulators of IgE- and MRGPRX2-Dependent Degranulation in Human Mast Cells.

Allergy·2026

Related Experiment Video

Updated: May 16, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Dendritic cell-based immunotherapy in mesothelioma.

Robin Cornelissen1, Lysanne A Lievense, Marlies E Heuvers

  • 1Department of Pulmonary Medicine, Erasmus MC, SV-125, PO-Box 2040, 3000 CA Rotterdam, The Netherlands. r.cornelissen@erasmusmc.nl

Immunotherapy
|November 15, 2012
PubMed
Summary

Mesothelioma immunotherapy shows promise, particularly using dendritic cells. Further research is needed to optimize these strategies for better patient outcomes in this rare thoracic cancer.

More Related Videos

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: May 16, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

  • Oncology
  • Immunology

Background:

  • Mesothelioma is a rare thoracic malignancy with poor prognosis and limited treatment options.
  • The immunogenic nature of mesothelioma suggests potential for immunotherapy.
  • Current clinical outcomes for mesothelioma remain disappointing.

Purpose of the Study:

  • To review current immunotherapeutic strategies for mesothelioma.
  • To provide a future perspective on improving mesothelioma therapy outcomes.
  • To highlight the role of dendritic cells in mesothelioma immunotherapy.

Main Methods:

  • Literature review of immunotherapy in mesothelioma.
  • Analysis of dendritic cell-based immunotherapeutic approaches.
  • Discussion of recent advancements in immuno-oncology for mesothelioma.

Main Results:

  • Significant progress has been made in understanding immune system modulation against tumors.
  • Dendritic cells demonstrate potent antigen-presenting capacity, making them promising for immunotherapy.
  • Optimal immunotherapy strategies for mesothelioma are still under investigation.

Conclusions:

  • Immunotherapy, especially using dendritic cells, offers a promising avenue for improving mesothelioma treatment.
  • Further research is essential to unravel the optimal immunotherapy strategy.
  • Advancements in immuno-oncology could significantly enhance patient prognosis for mesothelioma.